A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
12
05
2020
accepted:
30
07
2020
revised:
15
07
2020
pubmed:
26
8
2020
medline:
25
3
2021
entrez:
26
8
2020
Statut:
ppublish
Résumé
AsiDNA, a first-in-class oligonucleotide-mimicking double-stranded DNA breaks, acts as a decoy agonist to DNA damage response in tumour cells. It also activates DNA-dependent protein kinase and poly (adenosine diphosphate [ADP]-ribose) polymerase enzymes that induce phosphorylation of H2AX and protein PARylation. The aim of this Phase 1 study was to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), safety and pharmacokinetics/pharmacodynamics of AsiDNA administered daily for 3 days in the first week then weekly thereafter. Twenty-two patients with advanced solid tumours were enrolled in 5 dose levels: 200, 400, 600, 900, and 1300 mg, using a 3 + 3 design. The MTD was not reached. IV AsiDNA was safe. Two DLTs (grade 4 and grade 3 hepatic enzymes increased at 900 and 1300 mg), and two related SAE at 900 mg (grade 3 hypotension and grade 4 hepatic enzymes increased) were reported. AsiDNA PK increased proportionally with dose. A robust activation of DNA-PK by a significant posttreatment increase of γH2AX was evidenced in tumour biopsies. The dose of 600 mg was identified as the optimal dose for further clinical development. Clinical trial registration (NCT number): NCT03579628.
Sections du résumé
BACKGROUND
AsiDNA, a first-in-class oligonucleotide-mimicking double-stranded DNA breaks, acts as a decoy agonist to DNA damage response in tumour cells. It also activates DNA-dependent protein kinase and poly (adenosine diphosphate [ADP]-ribose) polymerase enzymes that induce phosphorylation of H2AX and protein PARylation.
METHODS
The aim of this Phase 1 study was to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), safety and pharmacokinetics/pharmacodynamics of AsiDNA administered daily for 3 days in the first week then weekly thereafter. Twenty-two patients with advanced solid tumours were enrolled in 5 dose levels: 200, 400, 600, 900, and 1300 mg, using a 3 + 3 design.
RESULTS
The MTD was not reached. IV AsiDNA was safe. Two DLTs (grade 4 and grade 3 hepatic enzymes increased at 900 and 1300 mg), and two related SAE at 900 mg (grade 3 hypotension and grade 4 hepatic enzymes increased) were reported. AsiDNA PK increased proportionally with dose. A robust activation of DNA-PK by a significant posttreatment increase of γH2AX was evidenced in tumour biopsies.
CONCLUSION
The dose of 600 mg was identified as the optimal dose for further clinical development.
CLINICAL TRIAL REGISTRATION
Clinical trial registration (NCT number): NCT03579628.
Identifiants
pubmed: 32839491
doi: 10.1038/s41416-020-01028-8
pii: 10.1038/s41416-020-01028-8
pmc: PMC7653034
doi:
Substances chimiques
DT01 compound
0
DNA
9007-49-2
Cholesterol
97C5T2UQ7J
Banques de données
ClinicalTrials.gov
['NCT03579628']
Types de publication
Clinical Trial, Phase I
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1481-1489Références
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L. et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11, 4912–4922 (2005).
doi: 10.1158/1078-0432.CCR-04-2088
Fischer, U. & Meese, E. Gliobastoma multiforme: the role of DSB repair between genotype and phenotype. Oncogene 26, 7809–7815 (2007).
doi: 10.1038/sj.onc.1210878
Kauffmann, A., Rosselli, F. & Lazar, V. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogne 27, 565–573 (2008).
doi: 10.1038/sj.onc.1210700
Bryant, H., Schultz, N. & Thomas, H. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913–917 (2005).
doi: 10.1038/nature03443
Farmer, H., McCabe, N. & Lord, C. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).
doi: 10.1038/nature03445
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235–244 (2010).
doi: 10.1016/S0140-6736(10)60892-6
Chiarugi, A. A snapshot of chemoresistance to PARP inhibitors. Trends Pharm. Sci. 33, 42–48 (2012).
doi: 10.1016/j.tips.2011.10.001
Quanz, M., Berthault, N., Roulin, C., Roy, M., Herbette, A., Agrario, C. et al. Small-molecule drugs mimicking DNA damage: a new strategy for sensitizing tumours to radiotherapy. Clin. Cancer Res. 15, 1308–1316 (2009).
doi: 10.1158/1078-0432.CCR-08-2108
Quanz, M., Chassoux, D., Berthault, N., Agrario, C., Sun, J. S. & Dutreix, M. Hyperactivation of DNA-PK by double-strand break mimicking molecules disorganizes DNA damage response. PLoS ONE 4, e6298 (2009).
doi: 10.1371/journal.pone.0006298
Croset, A., Cordelieres, F. P., Berthault, N., Buhler, C., Sun, J. S., Quanz, M. et al. Inhibition of DNA damage repair by artificial activation of PARP with siDNA. Nucleic Acids Res. 41, 7344–7355 (2013).
doi: 10.1093/nar/gkt522
Jdey, W., Thierry, S., Russo, C., Devun, F., Al Abo, M., Noguiez-Hellin, P. et al. Drug driven synthetic lethality: bypassing tumour cell genetics with a combination of Dbait and PARP inhibitors. Clin. Cancer Res. 23, 1001–1011 (2017).
doi: 10.1158/1078-0432.CCR-16-1193
Jdey, W., Thierry, S., Popova, T., Stern, M.-H. & Dutreix, M. Micronuclei frequency in tumors is a predictive biomarker for genetic instability and sensitivity to the DNA repair inhibitor AsiDNA. Cancer Res. 77, 4207–4216 (2017).
doi: 10.1158/0008-5472.CAN-16-2693
Herath, N., Devun, F., Lienafa, M. C., Herbette, A., Denys, A., Sun, J. S. et al. The DNA repair inhibitor DT01 as a novel therapeutic strategy for chemosensitization of colorectal liver metastasis. Mol. Cancer Ther. 15, 15–22 (2016).
doi: 10.1158/1535-7163.MCT-15-0408
Herath, N., Devun, F. & Herbette, A. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models. Eur. Radiol. 27, 4435–4444 (2017).
doi: 10.1007/s00330-017-4792-1
Herath, N. I., Berthault, N., Thierry, S., Jdey, W., Lienafa, M.-C., Bono, F. et al. Preclinical studies comparing efficacy and toxicity of DNA repair inhibitors, olaparib, and AsiDNA
doi: 10.3389/fonc.2019.01097
Jdey, W., Thierry, S. & Russo, C. Drug driven synthetic lethality: bypassing tumour cell genetics with a combination of Dbait and PARP inhibitors. Clin. Cancer Res. 23, 1001–1011 (2016).
doi: 10.1158/1078-0432.CCR-16-1193
Devun, F., Biau, J., Huerre, M., Croset, A., Sun, J.-S., Denys, A. et al. Colorectal cancer metastasis: the DNA repair inhibitor Dbait increases sensitivity to hyperthermia and improves efficacy of radiofrequency ablation. Radiology 270, 736–746 (2014).
doi: 10.1148/radiol.13130805
Jdey, W., Koslak, M., Alekseev, S., Thierry, S., Lascaux, P., Girard, P.-M. et al. AsiDNAtreatment induces cumulative antitumour efficacy with a low probability of acquired resistance. Neoplasia 21, 863–871 (2019).
doi: 10.1016/j.neo.2019.06.006
Le Tourneau, C., Dreno, B., Kirova, Y., Grob, J. J., Jouary, T., Dutriaux, C. et al. First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. Br. J. Cancer 114, 1199–1205 (2016).
doi: 10.1038/bjc.2016.120
Biau, J., Devun, F., Jdey, W., Kotula, E., Quanz, M., Chautard, E. et al. A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma. Neoplasia 16, 835–844 (2014).
doi: 10.1016/j.neo.2014.08.008
Crooke, S. T. Antisense Drug Technology: Principles, Strategies and Applications 2nd edn (CRC, 2008).
Furuta, T., Takemura, H. & Liao, Z. Phosphorylation of histone H2AX and activation ofMre11, Rad50, and Nbs1in response to replication-dependent DNA double- strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278, 20303–20312 (2003).
doi: 10.1074/jbc.M300198200
Olive, P. & Banath, J. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 58, 331–335 (2004).
doi: 10.1016/j.ijrobp.2003.09.028
Stiff., T., O'Driscoll, M., Rief, N., Iwabuchi, K., Lobrich, M. & Jeggo, P. A. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res. 64, 2390–2396 (2004).
doi: 10.1158/0008-5472.CAN-03-3207
Vilenchik, M. M. & Knudson, A. G. Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc. Natl Acad. Sci. USA 100, 12871–12876 (2003).
doi: 10.1073/pnas.2135498100
Sedelnikova, O. A., Rogakou, E. P., Panyutin, I. G. & Bonner, W. M. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat. Res. 158, 486–492 (2002).
doi: 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2
Nazarov, I. B., Smirnova, A. N., Krutilina, R. I., Svetlova, M. P., Solovjeva, L. V., Nikiforov, A. A. et al. Dephosphorylation of histone gamma-H2AX during repair of DNA double-strand breaks in mammalian cells and its inhibition by calyculin A. Radiat. Res. 160, 309–317 (2003).
doi: 10.1667/RR3043
Camphausen, K., Brady, K. & Burgan, W. Flavopiridol enhances human tumour cell radiosensitivity and prolongs expression of H2AX foci. Mol. Cancer Ther. 3, 409–416 (2004).
Girard, P. M. et al. Evolution of tumors cells during AsiDNA treatment results in energy exhausion, decrease in responsiveness to signal, and higher sensitivity to the drug. Evol. Appl. https://doi.org/10.1111/eva.12949 (2020).
Le Tourneau, C. et al. Phase I dose escalation study evaluating the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNA, a first-in-class DNA Repair Inhibitor, administered intravenously (IV) in patients with advanced solid tumors. Mol. Cancer Ther. https://doi.org/10.1158/1535-7163 (2019).